| 5.5 -0.1 (-1.79%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.59 | 1-year : | 8.86 |
| Resists | First : | 6.5 | Second : | 7.59 |
| Pivot price | 5.3  |
|||
| Supports | First : | 4.86 | Second : | 3.84 |
| MAs | MA(5) : | 5.45 |
MA(20) : | 5.22 |
| MA(100) : | 7.82  |
MA(250) : | 10.32 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 62.7 |
D(3) : | 61.9 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 28.44 | Low : | 3.84 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PAVM ] has closed below upper band by 40.1%. Bollinger Bands are 2.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.79 - 5.82 | 5.82 - 5.84 |
| Low: | 5.27 - 5.29 | 5.29 - 5.32 |
| Close: | 5.45 - 5.5 | 5.5 - 5.54 |
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
Tue, 07 Jul 2026
Price to sales forward of PAVmed Inc. – NASDAQ:PAVM - TradingView
Mon, 29 Jun 2026
PAVmed Inc.(NasdaqCM: PAVM) added to Russell Microcap Value Benchmark Index - marketscreener.com
Sun, 28 Jun 2026
PAVmed Inc.(NasdaqCM: PAVM) added to Russell 3000E Value Benchmark - marketscreener.com
Wed, 24 Jun 2026
PAVmed (PAVM) holders re-elect directors, expand ESPP shares and ratify CBIZ - Stock Titan
Thu, 18 Jun 2026
PAVmed Inc (PAVM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fri, 15 May 2026
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 5.2e+006 (%) |
| Held by Institutions | 44.1 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.431e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -36 % |
| Return on Assets (ttm) | 522.7 % |
| Return on Equity (ttm) | -31.1 % |
| Qtrly Rev. Growth | 85000 % |
| Gross Profit (p.s.) | 318.18 |
| Sales Per Share | -122.22 |
| EBITDA (p.s.) | -352727 |
| Qtrly Earnings Growth | -48.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0.53 |
| Dividend | 0 |
| Forward Dividend | 33650 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|